170 related articles for article (PubMed ID: 23664879)
1. Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.
Thalji RK; McAtee JJ; Belyanskaya S; Brandt M; Brown GD; Costell MH; Ding Y; Dodson JW; Eisennagel SH; Fries RE; Gross JW; Harpel MR; Holt DA; Israel DI; Jolivette LJ; Krosky D; Li H; Lu Q; Mandichak T; Roethke T; Schnackenberg CG; Schwartz B; Shewchuk LM; Xie W; Behm DJ; Douglas SA; Shaw AL; Marino JP
Bioorg Med Chem Lett; 2013 Jun; 23(12):3584-8. PubMed ID: 23664879
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds.
Sandanayaka V; Mamat B; Bhagat N; Bedell L; Halldorsdottir G; Sigthorsdottir H; Andrésson T; Kiselyov A; Gurney M; Singh J
Bioorg Med Chem Lett; 2010 May; 20(9):2851-4. PubMed ID: 20371179
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.
Shen HC; Ding FX; Deng Q; Xu S; Chen HS; Tong X; Tong V; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Zhang B; Roy S; Tata JR; Berger JP; Colletti SL
Bioorg Med Chem Lett; 2009 Sep; 19(18):5314-20. PubMed ID: 19682899
[TBL] [Abstract][Full Text] [Related]
4. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.
Shen HC; Ding FX; Wang S; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Chen X; Zhang B; Tata JR; Berger JP; Colletti SL
Bioorg Med Chem Lett; 2009 Jul; 19(13):3398-404. PubMed ID: 19481932
[TBL] [Abstract][Full Text] [Related]
5. Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase.
Anandan SK; Gless RD
Bioorg Med Chem Lett; 2010 May; 20(9):2740-4. PubMed ID: 20363133
[TBL] [Abstract][Full Text] [Related]
6. Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.
Eldrup AB; Soleymanzadeh F; Farrow NA; Kukulka A; De Lombaert S
Bioorg Med Chem Lett; 2010 Jan; 20(2):571-5. PubMed ID: 19969453
[TBL] [Abstract][Full Text] [Related]
7. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
Xin Z; Zhao H; Serby MD; Liu B; Liu M; Szczepankiewicz BG; Nelson LT; Smith HT; Suhar TS; Janis RS; Cao N; Camp HS; Collins CA; Sham HL; Surowy TK; Liu G
Bioorg Med Chem Lett; 2008 Aug; 18(15):4298-302. PubMed ID: 18632269
[TBL] [Abstract][Full Text] [Related]
8. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern.
Ostermann AI; Herbers J; Willenberg I; Chen R; Hwang SH; Greite R; Morisseau C; Gueler F; Hammock BD; Schebb NH
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):131-7. PubMed ID: 26117215
[TBL] [Abstract][Full Text] [Related]
9. Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT).
Ding Y; Belyanskaya S; DeLorey JL; Messer JA; Joseph Franklin G; Centrella PA; Morgan BA; Clark MA; Skinner SR; Dodson JW; Li P; Marino JP; Israel DI
Bioorg Med Chem; 2021 Jul; 41():116216. PubMed ID: 34023664
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase.
Penning TD; Chandrakumar NS; Desai BN; Djuric SW; Gasiecki AF; Liang CD; Miyashiro JM; Russell MA; Askonas LJ; Gierse JK; Harding EI; Highkin MK; Kachur JF; Kim SH; Villani-Price D; Pyla EY; Ghoreishi-Haack NS; Smith WG
Bioorg Med Chem Lett; 2002 Dec; 12(23):3383-6. PubMed ID: 12419366
[TBL] [Abstract][Full Text] [Related]
11. Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors.
Anandan SK; Do ZN; Webb HK; Patel DV; Gless RD
Bioorg Med Chem Lett; 2009 Feb; 19(4):1066-70. PubMed ID: 19168352
[TBL] [Abstract][Full Text] [Related]
12. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
Shen HC; Ding FX; Deng Q; Xu S; Tong X; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
Bioorg Med Chem Lett; 2009 Oct; 19(19):5716-21. PubMed ID: 19700315
[TBL] [Abstract][Full Text] [Related]
13. Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors.
Bryan MC; Whittington DA; Doherty EM; Falsey JR; Cheng AC; Emkey R; Brake RL; Lewis RT
J Med Chem; 2012 Feb; 55(4):1698-705. PubMed ID: 22263917
[TBL] [Abstract][Full Text] [Related]
14. Piperidine amides as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Flyrén K; Bergquist LO; Castro VM; Fotsch C; Johansson L; St Jean DJ; Sutin L; Williams M
Bioorg Med Chem Lett; 2007 Jun; 17(12):3421-5. PubMed ID: 17442567
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors.
Pecic S; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD; Zhu Z; Rinderspacher A; Deng SX
Bioorg Med Chem Lett; 2013 Jan; 23(2):417-21. PubMed ID: 23237835
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
[TBL] [Abstract][Full Text] [Related]
17. From a multipotent stilbene to soluble epoxide hydrolase inhibitors with antiproliferative properties.
Buscató E; Büttner D; Brüggerhoff A; Klingler FM; Weber J; Scholz B; Zivković A; Marschalek R; Stark H; Steinhilber D; Bode HB; Proschak E
ChemMedChem; 2013 Jun; 8(6):919-23. PubMed ID: 23596124
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of amide-phosphonate derivatives as inhibitors of the human soluble epoxide hydrolase.
Kim IH; Park YK; Nishiwaki H; Hammock BD; Nishi K
Bioorg Med Chem; 2015 Nov; 23(22):7199-210. PubMed ID: 26507430
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
Taylor SJ; Soleymanzadeh F; Eldrup AB; Farrow NA; Muegge I; Kukulka A; Kabcenell AK; De Lombaert S
Bioorg Med Chem Lett; 2009 Oct; 19(20):5864-8. PubMed ID: 19758802
[TBL] [Abstract][Full Text] [Related]
20. Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.
Pecic S; Zeki AA; Xu X; Jin GY; Zhang S; Kodani S; Halim M; Morisseau C; Hammock BD; Deng SX
Prostaglandins Other Lipid Mediat; 2018 May; 136():90-95. PubMed ID: 29567338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
